StonvexLoading…
StonvexStonvexStonvexCore line items from DBD's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $891.80M | $3.81B | $2.70B | $1.76B |
Operating Income | $32.70M | $242.00M | $159.60M | $85.80M |
Net Income | $5.00M | $94.60M | $45.00M | $3.90M |
EPS (Diluted) | $0.14 | $2.54 | $1.20 | $0.10 |
Total Assets | $3.83B | $3.85B | $3.72B | $3.74B |
Total Liabilities | $2.80B | $2.75B | $2.61B | $2.63B |
Cash & Equivalents | $358.60M | $368.90M | $246.10M | $279.20M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 34.75M | 35.38M | 36.20M | 36.86M |